Treatment Delays, Denials More Common in Prescriptions Initially Rejected

Why It Matters

The study quantifies how PA rejections translate into treatment delays and denials, underscoring a critical barrier to care that insurers and policymakers must address to balance cost control with patient access.

Key Takeaways

• 54% of initially rejected prescriptions eventually approved
• Same‑day approvals only 7% of all rejected fills
• Medicaid patients see highest same‑day approval but lowest overall rate
• Multiple PA review rounds reduce same‑day decisions
• Refills approved more often than first‑time fills

Pulse Analysis

Prior authorization was introduced as a cost‑containment tool, allowing insurers to vet the medical necessity of high‑priced brand drugs before they reach the pharmacy. While the mechanism can curb wasteful spending, the JAMA Health Forum analysis reveals a hidden cost: extensive processing times that translate into real‑world treatment delays for patients. By leveraging the IQVIA Formulary Impact Analyzer, researchers captured nearly 206,000 prescription events, showing that more than half of initially rejected claims eventually receive approval, yet only a fraction are cleared on the day of the request.

The data expose stark disparities across insurance categories and medication types. Medicaid beneficiaries experience the highest same‑day approval rate at 38%, but their overall approval lags behind Medicare and commercial plans, reflecting potential systemic inequities. Drugs such as ubrogepant achieve rapid clearance, whereas high‑cost biologics like evolocumab face slower pathways despite higher ultimate approval rates. Moreover, prescriptions requiring multiple PA rounds are significantly less likely to be resolved quickly, and additional rejection reasons further prolong the process, even though they may increase the chance of eventual approval. Clinicians must navigate these complexities, often submitting repeated documentation, which can strain provider resources and delay patient care.

For payers, the findings suggest a need to streamline PA workflows, especially for repeat prescriptions and high‑volume drugs, to reduce administrative burden without sacrificing fiscal oversight. Implementing automated decision engines, standardizing criteria, and offering transparent timelines could improve same‑day approval rates and overall patient satisfaction. Policymakers may consider regulatory reforms that mandate clear appeal processes and limit the number of PA iterations. As the healthcare landscape evolves toward value‑based care, balancing cost containment with timely access will be pivotal in ensuring that prior authorization serves its intended purpose rather than becoming a barrier to treatment.